mRNA: Decoding the Future Beyond Vaccines
Self-Amplifying RNA: Redefining RNA-Based Therapeutics The global RNA therapeutics market is slated to reach $940-$950 million by 2035. Out of several promising advancements driving this growth, self-amplifying RNA therapeutics are currently leading the pack. saRNA vaccines offer protective immunity at doses that are 1,000,000-fold lower than their mRNA counterparts, with optimized platforms in preclinical models. […]
IP Landscape – mRNA Characterization
A leading global biopharma company sought a comprehensive IP landscape review to identify market gaps and enhance its competitive edge. Stellarix’s consulting insights helped the client expand into new markets and strategically position their IP portfolio by highlighting high-value technologies and untapped areas for patent filing. Client Background: A global biopharma leader focused on immune […]
Protein Corona: The Unseen Force Shaping the Future of Nanomedicine
Unraveling the Mechanistic Blueprint of Protein Corona Formation Nanoparticles are transforming therapeutic and diagnostic methods, but their biological behavior remains largely dependent on the protein corona, i.e., the dynamic layer of proteins and biomolecules that adsorb to their surfaces shortly after exposure to a physiological environment. This protein corona, in turn, changes the nanoparticle’s identity, […]
IP Landscape- Lipid Nanoparticles for Biomolecules Delivery
A global pharmaceutical leader partnered with Stellarix to gain strategic insights into lipid nanoparticle (LNP) systems for biomolecule delivery. With LNPs emerging as a critical platform for mRNA, siRNA, and CRISPR-based therapeutics, recognized and regulated by the FDA—our case study mapped key components, formulation strategies, and advanced manufacturing practices. Client Background: The client is a […]
Beyond mRNA: How CircRNA Is Disrupting The Therapeutic Paradigm
Circular RNAs (CircRNA) are a naturally occurring, large family of stable single-stranded RNAs. They are a strongly emerging category in RNA therapeutics and are expected to outgrow their linear counterparts due to their low immunogenicity, higher stability, and stronger protein expression. Early research has scratched only the tip of the iceberg in the last few […]
mRNA Era – Crafting Personalized Healthcare
Over the past few years, messenger RNA (mRNA) has emerged as a transformative instrument in personalized medicine, particularly following the COVID-19 pandemic. Historically, personalized medicine has relied on the practice of designing therapies based on a patient’s genomic characteristics to provide the best treatment possible for a patient’s unique biological characteristics. mRNA technology has remarkably […]
H5N1 Avian Flu Outbreak: Current Ballgame
Globally, since 2020, avian flu has gained heightened attention as a probable epidemic that can be caused and, subsequently, a significant research-based momentum. H5N1 bird flu remains one of the major concerns due to its potential for cross-species transmission and severe impact on both avian and mammalian populations. Vigilance and research are crucial for understanding […]
mRNA-Based Gene Editing Therapeutics
Genome editing has been gaining importance since the last decade as a potential alternative to gene therapy. Nucleases (ZFNs, TALENs, etc.) and the CRISPR–Cas9 system provide powerful tools for site-specific modification of genomes. However, these approaches have the risk of nonspecific editing as the DNA-based vectors translate the enzymes involved. In-vitro transcribed mRNA (IVT mRNA) […]
Protein Replacement Therapy for Rare Disease
Overview Protein Replacement Therapy (PRT) offers a therapeutic approach for rare diseases caused by missing, deficient, or dysfunctional proteins. By supplying functional proteins or enabling their production within the body, these therapies aim to restore biological processes and address underlying disease mechanisms. Advances in recombinant protein engineering, enzyme replacement, mRNA delivery, and nanotechnology are expanding […]